Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years.

Eduardo Pons-FusterO Lozano-CaballeroS Martín-BalbuenaC Lucas-RódenasA Mancebo-GonzálezI De Gorostiza-FríasC M González-Ponce

Published in: International journal of clinical pharmacy (2024)

Anti-CGRP mAbs prove effectiveness and safety over a 24-month period in a RM population. Patients with no medication overuse and lower basal MMDs and MAM may respond better to anti-CGRP mAbs.

Keyphrases

randomized controlled trial
systematic review
emergency department
adverse drug